scispace - formally typeset
M

Marco Del Chiaro

Researcher at Anschutz Medical Campus

Publications -  224
Citations -  9245

Marco Del Chiaro is an academic researcher from Anschutz Medical Campus. The author has contributed to research in topics: Pancreatic cancer & Medicine. The author has an hindex of 35, co-authored 173 publications receiving 6273 citations. Previous affiliations of Marco Del Chiaro include University of Colorado Boulder & University of Colorado Denver.

Papers
More filters
Journal ArticleDOI

The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula : 11 Years After

TL;DR: This new definition and grading system of postoperative pancreatic Fistula should lead to a more universally consistent evaluation of operative outcomes after pancreatic operation and will allow for a better comparison of techniques used to mitigate the rate and clinical impact of a pancreatic fistula.
Journal ArticleDOI

European evidence-based guidelines on pancreatic cystic neoplasms

Marco Del Chiaro, +88 more
- 01 May 2018 - 
TL;DR: A conservative approach is recommended for asymptomatic MCN and IPMN, and Lifelong follow-up of IPMN is recommended in patients who are fit for surgery.
Journal ArticleDOI

MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity

TL;DR: Modulation of apoptosis, Akt phosphorylation, and expression of genes involved in invasive behavior may contribute to the role of miR-21 in gemcitabine chemoresistance and to the rational development of new targeted combinations.
Journal ArticleDOI

European experts consensus statement on cystic tumours of the pancreas.

TL;DR: Diagnostic computerized tomography and/or magnetic resonance imaging are indicated in all patients with cystic lesion of the pancreas and in lesions with a suspicion of malignancy, otherwise organ preserving procedures may be considered.
Journal ArticleDOI

Pancreatic adenocarcinoma, Version 2.2021

Margaret A. Tempero, +35 more
Abstract: Pancreatic cancer is the fourth leading cause of cancer-related death among men and women in the United States. A major challenge in treatment remains patients' advanced disease at diagnosis. The NCCN Guidelines for Pancreatic Adenocarcinoma provides recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with pancreatic cancer. Although survival rates remain relatively unchanged, newer modalities of treatment, including targeted therapies, provide hope for improving patient outcomes. Sections of the manuscript have been updated to be concordant with the most recent update to the guidelines. This manuscript focuses on the available systemic therapy approaches, specifically the treatment options for locally advanced and metastatic disease.